| Lipids Management |
0 |
0.84 |
| Statins |
0 |
0.67 |
| Hypertension |
0 |
0.51 |
| Adherence |
0 |
0.33 |
| Beta Blockers |
0 |
0.33 |
| Renin-Angiotensin System (RAS) |
0 |
0.5 |
| Atherosclerosis |
0 |
0.28 |
| Percutaneous Coronary Intervention (PCI) |
0 |
0.6 |
| Angiotensin II Receptor Blockade |
0 |
0.24 |
| ACE Inhibitor |
0 |
0.17 |
| Angina Pectoris |
0 |
0.17 |
| Artery |
0 |
0.17 |
| Blind Spot |
0 |
0.17 |
| Clinical Research |
0 |
0.17 |
| Insurance |
0 |
0.17 |
| Receptors |
0 |
0.17 |
| Retinal Diseases |
0 |
0.17 |
| Revenue and Practice Management |
0 |
0.17 |